Cyxone AB logo

Cyxone AB

Cyxone AB is developing novel cyclotide drugs for autoimmune including Multiple Sclerosis and other diseases.

Cyxone has acquired the cyclotide patent rights developed by the Medical University of Vienna and the University Medical Center of Freiburg.

[stock_market_widget type=”leaderboard” template=”color-frame” color=”yellow” assets=”4CX.F” api=”yf” style=”font-size: 15px”]

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://cyxone.com
Founded2015
Disease Focus
Development Stage
STOCK CODEFRA: 4CX
Address
Adelgatan 21221 22
Malmo
Sweden
Email
Contact Number
+46 70 71 68 009

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]

Cyxone use its cyclotide technology to find new structures that can benefit patients with other major diseases. Cyxone lead drug T20K is a synthesized plant peptide (cyclotide), and was extracted from a traditional medicinal plant,Oldenlandia affinis.

In 2017, Cyxone entered an acquisition agreement with OxyPharma for drug candidate Rabeximod in clinical phase II for RA. Cyxone issued approx 1.9Mn shares to complete the payment.